Collegium Pharmaceutical (NASDAQ:COLL) Sets New 12-Month Low – Here’s What Happened

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares reached a new 52-week low on Tuesday . The company traded as low as $28.30 and last traded at $28.30, with a volume of 534 shares changing hands. The stock had previously closed at $28.62.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Piper Sandler reissued a “neutral” rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.60.

Collegium Pharmaceutical Stock Performance

The stock has a market capitalization of $945.25 million, a price-to-earnings ratio of 12.63 and a beta of 0.82. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The firm has a fifty day moving average of $30.73 and a 200-day moving average of $34.07.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC raised its stake in Collegium Pharmaceutical by 124.5% during the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 792 shares during the period. CWM LLC raised its holdings in shares of Collegium Pharmaceutical by 97.5% during the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after buying an additional 736 shares during the period. TD Private Client Wealth LLC lifted its position in Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after acquiring an additional 483 shares in the last quarter. Virtus Fund Advisers LLC purchased a new position in Collegium Pharmaceutical in the 3rd quarter worth approximately $72,000. Finally, AXA S.A. acquired a new stake in Collegium Pharmaceutical in the second quarter valued at approximately $209,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.